Strategic Blueprint LLC Buys New Holdings in Amgen, Inc. (NASDAQ:AMGN)

Strategic Blueprint LLC bought a new stake in shares of Amgen, Inc. (NASDAQ:AMGN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 234 shares of the medical research company’s stock, valued at approximately $45,000.

Other hedge funds also recently modified their holdings of the company. Gifford Fong Associates lifted its stake in shares of Amgen by 25.3% in the 2nd quarter. Gifford Fong Associates now owns 67,671 shares of the medical research company’s stock valued at $12,470,000 after purchasing an additional 13,671 shares during the period. Bray Capital Advisors lifted its position in shares of Amgen by 11.6% in the second quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock valued at $3,626,000 after acquiring an additional 2,045 shares in the last quarter. Weaver Consulting Group purchased a new position in shares of Amgen in the first quarter valued at about $239,000. CHICAGO TRUST Co NA lifted its position in shares of Amgen by 2.8% in the second quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock valued at $685,000 after acquiring an additional 100 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in shares of Amgen by 4.0% in the second quarter. Private Advisor Group LLC now owns 38,488 shares of the medical research company’s stock valued at $7,093,000 after acquiring an additional 1,494 shares in the last quarter. Institutional investors own 76.32% of the company’s stock.

Several equities analysts have recently commented on AMGN shares. Credit Suisse Group restated an “outperform” rating and issued a $225.00 price objective (up from $202.00) on shares of Amgen in a research report on Friday, August 16th. BMO Capital Markets set a $240.00 target price on Amgen and gave the stock a “buy” rating in a report on Monday, September 30th. Citigroup reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 12th. Cantor Fitzgerald set a $230.00 target price on Amgen and gave the stock a “hold” rating in a report on Monday, September 30th. Finally, Royal Bank of Canada reaffirmed a “hold” rating on shares of Amgen in a report on Monday, September 30th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Amgen currently has an average rating of “Buy” and a consensus price target of $217.28.

In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total transaction of $413,400.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at approximately $2,990,141.44. The disclosure for this sale can be found here. Insiders have sold 17,851 shares of company stock worth $3,671,900 over the last three months. 0.25% of the stock is currently owned by insiders.

NASDAQ AMGN traded down $2.17 during trading hours on Friday, hitting $201.41. 846,948 shares of the company were exchanged, compared to its average volume of 2,190,518. The stock has a 50-day moving average price of $199.56 and a 200 day moving average price of $186.74. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $211.90. The stock has a market cap of $122.09 billion, a PE ratio of 13.99, a price-to-earnings-growth ratio of 2.66 and a beta of 1.11.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the firm posted $3.83 earnings per share. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Amgen, Inc. will post 14.33 earnings per share for the current year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: What is a price target?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.